Cinpanemab

• Description :

  Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2].

• CAS Number :

  [2094516-02-4]

• Product Name Alternative :

  BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)

• UNSPSC :

  12352203

• Target :

  α-synuclein

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/cinpanemab.html

• Purity :

  99.0

• Solubility :

  H2O

• Smiles :

  [Cinpanemab]

• Molecular Weight :

  (146.98 kDa)

• References & Citations :

  [1]Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387 (5) :408-420. |[2]Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20 (9) :802-813.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• Isoform :

  α-synuclein